

Richard Chesworth



Richard Chesworth DPhil. is currently the Executive Director of Molecular Discovery at Epizyme Inc. where his responsibilities include heading up the medicinal chemistry, lead discovery, DMPK as well as the protein and structural science departments. Richard obtained his BSc degree in Chemistry from Imperial College, University of London and his DPhil from Oxford University (Prof. Sir Jack Baldwin) followed by post-doctoral studies at Columbia University (advisor Prof. Gilbert Stork. Richard then embarked on his industrial career starting Pfizer in Groton, CT where he was a member of the metabolic diseases group working on a variety of drug classes including GPCR's, proteases and nuclear hormones. Richard left Pfizer for SurfaceLogix before joining EnVivo Pharmaceuticals (now Forum Pharmaceuticals, a CNS focused company where Richard worked on the $\alpha 7$ agonist EVP-6124 which is currently in Phase III clinical trials for both Schizophrenia and Alzheimer's Disease as well as HDAC inhibitors for CNS diseases, gamma-secretase modulators for Alzheimer's Disease and PDE-10 inhibitors for Schizophrenia. Richard joined Epizyme in 2010 to work on protein methyl transferase inhibitors where his group have delivered the first two histone methyl transferases into clinic development EPZ-5676 a DOT1L inhibitor for mixed lineage leukemia and EPZ-6438 (E7438) an EZH2 inhibitor for non-Hodgkin lymphoma and a variety of INI1-deficient tumors including synovial sarcoma and malignant rhabdoid tumors

Education

BSc Imperial College, London 1988-91

DPhil Oxford university 1991-94 (advisor Prof. Sir Jack Baldwin)

Post-Doc Columbia University 1995-1997 (advisor Prof. Gilbert Stork)

Pharma Career

Pfizer 1997-2004

Surfacelogix 2004-2005

Envivo (Forum Pharmaceuticals) 2005-2009

Epizyme 2010-present